Amarin Corp Plc price to book ratio AMRN

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 0.6×
10-year median: 0.9×
Against its 10-year history: 14th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.3× to 62.4×
Peer median: 2.2×

Amarin Corp Plc's price to book ratio is 0.6× as of Oct 23, 2026.

That is below its ten-year median of 0.9×, lower than on 86% of days in the last ten years.

Over that time it ranged from 0.3× in Apr 2025 to 62.4× in Feb 2017.

The median for 10 large drugmakers of a similar size is 2.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.6×	0.5×	0.8×
2025	0.6×	0.3×	0.9×
2024	0.3×	0.3×	1.0×
2023	0.6×	0.5×	1.4×
2022	0.8×	0.8×	2.3×
2021	2.1×	2.1×	5.4×
2020	3.1×	2.5×	12.6×
2019	13.0×	10.5×	54.4×
2018	n/m a value too high to mean anything
2017	59.1×	52.3×	62.4×
2016	54.8×	50.0×	60.8×

Against its peers

Companies in Drug Manufacturers - General nearest Amarin Corp Plc's size, closest first, today.

Company	Price to book ratio
AMRNAmarin Corp Plc	0.6×
NATRNatures Sunshine Products	1.3×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
Peer median	2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Amarin Corp Plc

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.